transforming what's possible
Setting a new
global standard in urological care.
Our image-guided, non-invasive technology redefines what is now possible in urology, providing a clear path to care without fear or compromise, benefiting patients, physicians, and the healthcare system alike.
Truly non-invasive
Treatment is delivered from outside the body. No penis penetration, no cutting, no risk of urethral strictures.
First-line treatment
Replaces long-term medication, avoiding side effects, sexual dysfunction, and reduced efficacy.
Dignified and comfortable
Designed for the clinic as an office treatment or in a hospital, no general anesthesia, no overnight stay.
The wait is finally over
For millions delaying care, NINA makes early treatment a clear choice, acceptable and effective.
confident patient experience
A treatment patients will say yes to.
Non-invasive and comfortable care designed around the patient.
For too long, men have had to choose between invasive treatments or delay
in fear and discomfort. With NINA Medical’s truly non-invasive approach,
there is no need to compromise.
in fear and discomfort. With NINA Medical’s truly non-invasive approach,
there is no need to compromise.
Patients remain awake and comfortable while focused ultrasound energy
is precisely guided in real time to gently reduce the prostate, enabling a reassuring patient-centered experience.
Unlike all existing procedures that enter through the urethra or rectum, NINA’s treatment reaches the prostate from outside the body, through the perineum, without penetration. The unique perineum acoustic window allows safe treatment of the prostate while sparing sensitive surrounding organs and tissue.
is precisely guided in real time to gently reduce the prostate, enabling a reassuring patient-centered experience.
Unlike all existing procedures that enter through the urethra or rectum, NINA’s treatment reaches the prostate from outside the body, through the perineum, without penetration. The unique perineum acoustic window allows safe treatment of the prostate while sparing sensitive surrounding organs and tissue.
NINA’s technological breakthrough extends far beyond clinical benefit;
it opens a vast new segment of the market. Millions of men who delay treatment finally have a reason to seek care early.
it opens a vast new segment of the market. Millions of men who delay treatment finally have a reason to seek care early.
Office-based simplicity
NINA brings precision therapy into the urology clinic, no OR, anesthesia,
or hospital overhead.
or hospital overhead.
All-in-one platform
Real-time imaging and therapeutic
targeting in a single device, controlled from a desktop console.
targeting in a single device, controlled from a desktop console.
Streamlined workflow
Improved throughput, reduced
procedure time, and faster patient
turnover, without complexity.
procedure time, and faster patient
turnover, without complexity.
Expanded patient base
Attract new patients who previously
refused invasive options, with a
solution they’ll accept.
refused invasive options, with a
solution they’ll accept.
streamlined for Physicians
Built for physicians' in-clinic care.
A simple, office-based solution that integrates seamlessly into modern practice.
NINA is transforming prostate care by combining imaging and therapy in a single unit. This truly non-invasive system allows urologists to assess and treat the prostate from the same platform, streamlining workflows and bringing new confidence to prostate care.
A robotic transperineal ultrasound scan provides precise, real-time visualization, introducing an advanced diagnostic alternative to traditional Digital Rectal Examination (DRE) for early-stage evaluation. Controlled entirely from a desktop console, NINA enables both examination and treatment to be performed intuitively from the physician’s desk.
NINA’s innovative workflow is designed to increase efficiency, enhance the patient experience, and expand access to care, restoring comfort and dignity to prostate care and engaging men who previously avoided urology visits. By integrating diagnostics and therapy seamlessly, NINA empowers physicians to develop their practice, expand their services, and reach more patients.
A robotic transperineal ultrasound scan provides precise, real-time visualization, introducing an advanced diagnostic alternative to traditional Digital Rectal Examination (DRE) for early-stage evaluation. Controlled entirely from a desktop console, NINA enables both examination and treatment to be performed intuitively from the physician’s desk.
NINA’s innovative workflow is designed to increase efficiency, enhance the patient experience, and expand access to care, restoring comfort and dignity to prostate care and engaging men who previously avoided urology visits. By integrating diagnostics and therapy seamlessly, NINA empowers physicians to develop their practice, expand their services, and reach more patients.
Category defining
NINA leads a new standard of care in a $20B+ untapped and overlooked
market segment.
market segment.
Clinical and strategic momentum
Preclinical success, preliminary clinical study completed, and first-in-human trial launched in 2025.
Strong IP and leadership
Backed by multiple patents, an experienced founding team, and an industry-leading board of directors.
Scalable Technology
NINA’s technology has the potential to expand across multiple medical fields and make a significant impact.
STRATEGIC MARKET OPPORTUNITY
Unlocking a $20B+ market
Breakthrough technology creating investor opportunities in a dynamic market.
NINA Medical is poised to redefine the $20B+ BPH market, one of the most dynamic segments in urology, driven by the rapid adoption of office-based solutions including UroLift, Rezūm, and iTind. The segment also reflects a clear shift toward less-invasive, patient-centric care.
Our non-invasive solution provides unmatched differentiation that resonates with payers, providers, and patients. The system combines imaging, robotics, and focused ultrasound in a single platform built on deep technological foundations and is adaptable to additional applications in urology and beyond.
The company’s pay-per-use model aligns with existing reimbursement frameworks for office-based BPH procedures, driving recurring revenue and reducing adoption barriers for physicians.
Strong market validation is evident in recent acquisitions by industry leaders, including Olympus (Medi-Tate), Boston Scientific (NxThera, Lumenis Surgical), and Laborie (Urotronic), highlighting the strategic demand for breakthrough technologies.
Our non-invasive solution provides unmatched differentiation that resonates with payers, providers, and patients. The system combines imaging, robotics, and focused ultrasound in a single platform built on deep technological foundations and is adaptable to additional applications in urology and beyond.
The company’s pay-per-use model aligns with existing reimbursement frameworks for office-based BPH procedures, driving recurring revenue and reducing adoption barriers for physicians.
Strong market validation is evident in recent acquisitions by industry leaders, including Olympus (Medi-Tate), Boston Scientific (NxThera, Lumenis Surgical), and Laborie (Urotronic), highlighting the strategic demand for breakthrough technologies.
latest publications
